Topics

Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment meets primary and key secondary endpoints

05:36 EDT 30 May 2019 | Pharmaceutical Business Review

In this multicenter, randomized, double-blind phase III QUARTZ study (ClinicalTrials.gov Identifier: NCT02892344), once-daily, low dose IND/MF (QMF149) 150/80 Mu g met the primary and key secondary endpoints (trough

The post Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment meets primary and key secondary endpoints appeared first on Pharmaceutical Business review.

Original Article: Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment meets primary and key secondary endpoints

NEXT ARTICLE

More From BioPortfolio on "Novartis’ phase III QUARTZ study of new investigational inhaled combination treatment meets primary and key secondary endpoints"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...